PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 47
- Locations
- 1
- Primary Endpoint
- Progression-free survival
Study Overview
Brief Summary
Young patients with relapsed or refractory classic Hodgkin's lymphoma will be treated with PD-1 inhibitor combined with decitabine as second-line salvage treatment for four cycles. If PR or CR was obtained after salvage treatment, patients will receive GBM conditioning regimen followed by ASCT as consolidation therapy. High-risk R/R cHL patients will be treated with PD-1 inhibitor after ASCT for 1 year. The purpose of current study is to determine the clinical efficacy and safety of PD-1 inhibitor combined with decitabine followed by ASCT as second-line treatment in patients with relapsed or refractory classic Hodgkin's lymphoma.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects must have histological confirmation of relapsed or refractory classic Hodgkin lymphoma (HL).
- •18 to 65 years of age.
- •Subjects with lymphoma must have at least one measureable lesion >1 cm as defined by lymphoma response criteria.
- •Proper functioning of the major organs: 1) The absolute value of neutrophils (≥1×10^9/L); 2) platelet count (≥75×10^9/L); 3) Serum creatinine <1.5 times Upper Limit Normal (ULN) ; 4) Serum total bilirubin < 1.5 times ULN; 5) Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) ≤3 times ULN; 6) Serum creatinine (Cr) ≤2 ULN, or glomerular filtration rate ≥40ml/min; 7) Thyrotropin (TSH) or free thyroxine (FT4) or free triiodothyronine (FT3) were all within the normal range (±10%).
- •Eastern Cooperative Oncology Group (ECOG) Performance status 0-
- •LVEF value measured by echocardiography ≥50%.
- •Life expectancy > 3 months.
Exclusion Criteria
- •Patients with central nervous system involvement by lymphoma.
- •Patients with active autoimmune diseases requiring systematic treatment in the past two years (hormone replacement therapy is not considered systematic treatment, such as type I diabetes mellitus, hypothyroidism requiring only thyroxine replacement therapy, adrenocortical dysfunction or pituitary dysfunction requiring only physiological doses of glucocorticoid replacement therapy); Patients with autoimmune diseases who do not require systematic treatment within two years can be enrolled.
- •Known systemic vasculitides, primary or secondary immunodeficiency(such as HIV infection or severe inflammatory disease).
- •Pregnant or breastfeeding women.
- •Major surgery within 4 weeks before enrollment.
- •Impaired cardiac function:Ejection fraction <50% on MUGA scan. QTc interval > 450msecs on baseline ECG. Myocardial infarction within 6 months prior to starting study; other clinically significant heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension, uncontrolled arrhythmias).
- •Other concurrent severe and/or uncontrolled medical conditions: Patients with another primary malignant disease, except those that do not currently require treatment; acute or chronic liver, pancreatic or severe renal disease; another severe and/or life-threatening medical disease.
Arms & Interventions
PD-1 inhibitor combined with decitabine followed by ASCT
Patients will receive salvage treatment of PD-1 inhibitor Tislelizumab combined with decitabine for four cycles, If PR or CR was obtained after salvage treatment, patients will receive GBM (gemcitabine, bulsufan and melphalan) conditioning regimen followed by ASCT. High-risk patients will receive PD-1 inhibitor for 1 year after ASCT as maintenance therapy.
Intervention: PD-1 inhibitor (Drug)
Outcomes
Primary Outcomes
Progression-free survival
Time Frame: 2 years
PFS
Secondary Outcomes
- Overall survival rate(2 years)
- Duration of response(2 years)
- Complete response rate(2 years)
- Objective response rate(2 years)
- Severity of the adverse events(2 years)
Investigators
Zou Dehui
Assistant Director of lymphoma Diagnosis and Treatment Center
Institute of Hematology & Blood Diseases Hospital, China